RecruitingACTRN12606000396527

Hepatitis B immunity and response to a booster dose of hepatitis B vaccine in Indigenous children who recieved hepatitis B vaccines in infancy


Sponsor

National Centre for Immunisation Research and Surveillance

Enrollment

450 participants

Start Date

Apr 1, 2006

Study Type

Interventional

Conditions

Summary

Adolescent enrolled in the Aboriginal Birth Cohort Study will have their serology to hepatitis B measured. Adolescents who received hepatitis B vaccines in infancy and have low immunity will be offered booster doses of the vaccine and have their immunity measured 2-4 weeks post vaccination.


Eligibility

Sex: Both males and femalesMin Age: 16 YearssMax Age: 19 Yearss

Plain Language Summary

Simplified for easier understanding

This study is checking whether Aboriginal and Torres Strait Islander adolescents who received hepatitis B vaccines as babies still have adequate protection against hepatitis B infection. These participants were originally enrolled in a study called the Aboriginal Birth Cohort (ABC). The study will measure their current antibody levels, and those with low immunity will be offered booster doses of the hepatitis B vaccine to restore their protection. You may be eligible if: - You are between 16 and 19 years old - You were originally enrolled in the Aboriginal Birth Cohort (ABC) study You may NOT be eligible if: - You were not enrolled in the original Aboriginal Birth Cohort study - You do not agree to having your hepatitis B antibody level tested at baseline - Booster vaccination is only available to participants whose antibody level is below 10 IU/mL Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Adolescents with low immunity will be offered booster doses of the vaccine and have their immunity measured 2-4 weeks post vaccination. HBVaxII 10microgram dose vaccine will be administered intramsuc

Adolescents with low immunity will be offered booster doses of the vaccine and have their immunity measured 2-4 weeks post vaccination. HBVaxII 10microgram dose vaccine will be administered intramsucularly in this study Study duration is 1 month approximately


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000396527